Last September, Brean Capital LLC reflected Wall Street's generally sour sentiment by downgrading from "buy" to "hold" shares of Tetraphase Pharmaceuticals Inc. pending "a clearer path forward," after the failure of the phase III study called IGNITE2 with eravacycline as an intravenous (I.V.)-to-oral transition therapy for complicated urinary tract infection (cUTI).